 Cytoplasmic bacteriophage display system |
| The present invention relates, in one aspect, to a display vector comprising DNA encoding a portion ... |
|
| Diagnosis of alzheimer disease stage by mononuclear cell cytokine secretions |
| AND ADVANTAGES According to the present invention, a method of diagnosing and determining the ... |
|
| Polyvalent display libraries |
| I. General The present invention is directed to inter alia two related but self-sufficient ... |
|
| Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus |
| OF THE INVENTION A. Definitions Amino Acid Residue: An amino acid formed upon chemical digestion (... |
|
| Pharmaceutical and diagnostic business systems and methods |
| Improved business methods, devices, and systems for utilizing genetic information are provided. A... |
|
| Method of differential display of exposed mRNA by RT/PCR |
| We claim: 1. A method of comparing the presence or level of individual mRNA molecules in two or ... |
|
| Methods of screening for compounds that derepress or increase telomerase activity |
| We claim: 1. Method for screening for a telomerase derepression agent, the method comprising the ... |
|
| Oral vaccines |
| What is claimed is: 1. A protein conjugate comprising an immunogen covalently linked to a carrier ... |
|
| Method for identifying validated target and assay combinations for drug development |
| The invention relates to methods that couple the validation of a target (see Definitions) for drug ... |
|
|
Method of delivering powder transdermally with needless injector
| Details |
Inventors: Bellhouse, Brian J.; Sarphie, David F.; Greenford, John C.;
Assignee: Oxford Biosciences Limited (Oxford, GB2)
Primary Examiner: Bockelman; Mark
Assistant Examiner:
Attorney, Agent or Firm: Reed & Robins
A needleless syringe having a membrane which is ruptured by gas pressure to generate a supersonic gas flow in which particles containing a therapeutic agent are injected. This provides effective transdermal delivery of the therapeutic agent. |
|
DETAILED DESCRIPTION What we claim is: 1.
A method of therapeutic treatment, comprising transdermally delivering particles of a powdered therapeutic agent across skin tissue of a mammalian subject, said particles being delivered to the locus of transdermal administration at a velocity in the range of between 200 and 2,500 m/sec, in which the particles of the therapeutic agent have a size predominantly in the range of about 10 to 250 .
mu.
m and a density in the range of 0.
1 to 25 g/cm.
sup.
3.
2.
A method according to claim 1, wherein the velocity range is between 500 and 1,500 m/sec.
3.
A method according to claim 2, wherein the velocity range is between 750 and 1000 m/sec.
4.
A method according to claim 1, wherein the size range is between 10 and 20 .
mu.
m.
5.
A method according to claim 1, wherein the density range is between 0.
5 and 2.
0 g/cm.
sup.
3.
6.
A method according to claim 1, in which the particles of the therapeutic agent are comprised of a stable mixture of drugs which are unstable when mixed wet.
7.
A method according to claim 1, wherein the therapeutic agent comprises insulin.
8.
A method according to claim 1, in which the particles of the therapeutic agent are in the form of spherical shells.
9.
A method according to claim 1, wherein the mammalian subject is human.
10.
A method of therapeutic treatment, comprising transdermally delivering particles of a powdered therapeutic agent across skin tissue of a mammalian subject, wherein said particles have a size predominantly in the range of about 10 to 250 .
mu.
m and are delivered to the locus of transdermal administration at a momentum density of between 2 and 10 kg/sec/m.
11.
A method according to claim 10, wherein the momentum density is between 4 and 7 kg/sec/m.
12.
A method according to claim 10, wherein the mammalian subject is human.
13.
A method of therapeutic treatment, comprising transdermally delivering particles of a powdered therapeutic agent combined with an inert carrier or diluent across skin tissue of a mammalian subject, said particles being delivered to the locus of transdermal administration at a velocity in the range of between 200 and 2,500 m/sec, in which the particles of the therapeutic agent have a size predominantly in the range of about 10 to 250
|
| Related patents |
|
|
Telomere repeat binding factors and diagnostic and therapeutic use thereof
The present invention provides vertebrate telomeric binding factors (TRFs) that bind to the TTAGGG repeat sequences of telomeres. Such TRFs comprise two key domains: a ...
|
|
|
Protease-activated receptor PAR4 (ZCHEMR2)
What is claimed is: 1. An isolated polynucleotide molecule that encodes a polypeptide comprising amino acid residues 48 to 78 of SEQ ID NO:2. 2. The isolated ...
|
|
|
Systemic drug delivery compositions comprising a polycationi substance
I claim: 1. A method of systemically delivering a pharmaceutically effective amount of a pharmacologically active compound to a mammal comprising: administering to a ...
|
|
|
Nucleic acid-containing composition, its preparation and use
We claim: 1. A composition comprising a deoxyribonucleic acid and a cationic oligopeptide that forms secondary structures, wherein the oligopeptide corresponds to the ...
|
|
|
Peptide-enhanced cationic lipid transfections
OF THE INVENTION The present invention provides improved methods for transfecting eukaryotic cells with nucleic acids by employing peptides or modified peptides in ...
|
|
|
Controlled release formulations coated with aqueous dispersions of acrylic polymers
It is therefore an object of the present invention to provide a controlled release formulation of a substrate comprising an active agent, e.g. a therapeutically active ...
|
|
|
Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides
What is claimed is: 1. A compound having the formula I: ##STR5## wherein, R.sub.1 is OH, O--R.sub.3, C--R.sub.3, halo, NHR.sub.4, ONHR.sub.5 or ON.dbd.R.sub.6, wherein R....
|
|
|
Substituted indazole-O-glucosides
OF THE INVENTION All diabetics, regardless of their genetic and environmental backgrounds, have in common an apparent lack of insulin or inadequate insulin function. B...
|
|
|
Production in Escherichia coli of extracellular Serratia spp. hydrolases
We claim: 1. A method of producing an extracellular hydrolytic Serratia spp. enzyme selected from the group consisting of exocellular nuclease, exocellular phospholipase ...
|
|
|
Modular assembly of antibody genes, antibodies prepared thereby and use
What is claimed is: 1. A polynucleotide molecule encoding an immunoglobulin fragment, said immunoglobulin fragment comprising a first DNA sequence encoding a first ...
|
|
|
Gene Therapy 
